(Reuters) – Moderna reported a greater quarterly loss on Friday than expected, the vaccine manufacturer having been penalized by a charge linked to his efforts to reduce production, in a context of decline in demand for his vaccine Against the COVID-19.

The group recorded a loss of $ 2.91 per share, beyond the loss of 2.68 dollars per share expected by analysts, according to LSEG data, and after a profit of $ 0.55 per share it a year ago.

During an interview, the financial director James Mock awarded this loss to an out -of -cash flow of 238 million dollars (227.45 million euros) linked to the termination of his agreement with a contract under contract.

“By examining our industrial footprint, we estimated that we did not need (this manufacturer) in particular and we tried to eliminate the potential waste linked to this capacity,” he said, refusing to Identify the manufacturer in question.

The Moderna title dropped by around 3% on Friday in the exchange before the Stock Exchange.

Moderna’s total quarterly turnover plummeted by almost 66% to fall to $ 966 million, but exceeded the expectations of analysts who were tabling out of $ 942.84 million.

Sales included $ 923 million for the COVVI-19 and $ 15 million vaccine for its VRS vaccine.

The company said that this decline was mainly due to the early launch of its COVVI-19 vaccine updated in the United States, which has moved sales to the third quarter, but also to the drop in international sales.

Treasury, cash equivalents and investments will reach $ 9.5 billion at the end of 2024, according to the group.

The group provides for the approval of its VRS vaccine for adults at high risk from 18 to 59 years this year.

(Mariam Sunny, Christy Sathosh and Patrick Wingrove; Elena Smirnova, edited by Augustin Turpin)

Copyright © 2025 Thomson Reuters